BACKGROUND: A diagnosis of breast cancer and treatment are psychologically stressful events, particularly over the first year after diagnosis. Women undergo many demanding and anxiety-arousing treatments such as surgery, radiation and chemotherapy. Psychosocial interventions that promote psychosocial adaptation to these challenges may modulate physiological processes (neuroendocrine and immune) that are relevant for health outcomes in breast cancer patients. METHODS:Women with Stages 1-3 breast cancer recruited 4-8 weeks after surgery were randomized to either a 10-week group-based cognitive behavioral stress management (CBSM) intervention or a 1-day psychoeducational control group and completed questionnaires and late afternoon blood samples at study entry and 6 and 12 months after assignment to experimental condition. RESULTS: Of 128 women initially providing psychosocial questionnaire and blood samples at study entry, 97 provided complete data for anxiety measures and cortisol analysis at all time points, and immune assays were run on a subset of 85 of these women. Those assigned to a 10-week group-based CBSM intervention evidenced better psychosocial adaptation (lower reported cancer-specific anxiety and interviewer-rated general anxiety symptoms) and physiological adaptation (lower cortisol, greater Th1 cytokine [interleukin-2 and interferon-gamma] production and IL-2:IL-4 ratio) after their adjuvant treatment compared to those in the control group. Effects on psychosocial adaptation indicators and cortisol appeared to hold across the entire 12-month observation period. Th1 cytokine regulation changes held only over the initial 6-month period. CONCLUSIONS: This intervention may have facilitated a "recovery or maintenance" of Th1 cytokine regulation during or after the adjuvant therapy period. Behavioral interventions that address dysregulated neuroendocrine function could play a clinically significant role in optimizing host immunologic resistance during a vulnerable period.
RCT Entities:
BACKGROUND: A diagnosis of breast cancer and treatment are psychologically stressful events, particularly over the first year after diagnosis. Women undergo many demanding and anxiety-arousing treatments such as surgery, radiation and chemotherapy. Psychosocial interventions that promote psychosocial adaptation to these challenges may modulate physiological processes (neuroendocrine and immune) that are relevant for health outcomes in breast cancerpatients. METHODS:Women with Stages 1-3 breast cancer recruited 4-8 weeks after surgery were randomized to either a 10-week group-based cognitive behavioral stress management (CBSM) intervention or a 1-day psychoeducational control group and completed questionnaires and late afternoon blood samples at study entry and 6 and 12 months after assignment to experimental condition. RESULTS: Of 128 women initially providing psychosocial questionnaire and blood samples at study entry, 97 provided complete data for anxiety measures and cortisol analysis at all time points, and immune assays were run on a subset of 85 of these women. Those assigned to a 10-week group-based CBSM intervention evidenced better psychosocial adaptation (lower reported cancer-specific anxiety and interviewer-rated general anxiety symptoms) and physiological adaptation (lower cortisol, greater Th1 cytokine [interleukin-2 and interferon-gamma] production and IL-2:IL-4 ratio) after their adjuvant treatment compared to those in the control group. Effects on psychosocial adaptation indicators and cortisol appeared to hold across the entire 12-month observation period. Th1 cytokine regulation changes held only over the initial 6-month period. CONCLUSIONS: This intervention may have facilitated a "recovery or maintenance" of Th1 cytokine regulation during or after the adjuvant therapy period. Behavioral interventions that address dysregulated neuroendocrine function could play a clinically significant role in optimizing host immunologic resistance during a vulnerable period.
Authors: J S Miller; J Tessmer-Tuck; B A Pierson; D Weisdorf; P McGlave; B R Blazar; E Katsanis; C Verfaillie; J Lebkowski; J Radford; L J Burns Journal: Biol Blood Marrow Transplant Date: 1997-04 Impact factor: 5.742
Authors: Michael H Antoni; Sarah R Wimberly; Suzanne C Lechner; Aisha Kazi; Tammy Sifre; Kenya R Urcuyo; Kristin Phillips; Roselyn G Smith; Vida M Petronis; Sophie Guellati; Kurrie A Wells; Bonnie Blomberg; Charles S Carver Journal: Am J Psychiatry Date: 2006-10 Impact factor: 18.112
Authors: Susan K Lutgendorf; Elizabeth Mullen-Houser; Daniel Russell; Koen Degeest; Geraldine Jacobson; Laura Hart; David Bender; Barrie Anderson; Thomas E Buekers; Michael J Goodheart; Michael H Antoni; Anil K Sood; David M Lubaroff Journal: Brain Behav Immun Date: 2010-06-30 Impact factor: 7.217
Authors: Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson Journal: Cancer Date: 2018-05-14 Impact factor: 6.860
Authors: Frank J Penedo; Michael H Antoni; Patricia I Moreno; Lara Traeger; Dolores Perdomo; Jason Dahn; Gregory E Miller; Steve Cole; Julian Orjuela; Edgar Pizarro; Betina Yanez Journal: Contemp Clin Trials Date: 2018-07-09 Impact factor: 2.226